CHANGES OF GELATINASES ACTIVITY IN RATS WITH ANTHRACYCLINE CARDIOPATHY AT APPLICATION OF NONSTEROID ANTIINFLAMMATORY DRUGS AND QUERCETIN
DOI: http://dx.doi.org/10.30970/sbi.0403.115
Abstract
The activity of gelatinases A and B in blood plasma of rats with doxorubicin-induced cardiopathy at the application of cyclooxygenases inhibitors – ketorolak, lornoxycam and celecoxib was investigated. Significant increase of activity of both gelatinases in rats with cardiopathy was identified. Under ketorolak effect gelatinase B activity increases, and gelatinase A is inhibited. The opposite reaction was observed when celecoxib was applied: gelatinase B activity decreases, and gelatinase A increases. Combination of bioflavonoid quercetin and COX inhibitors decreased the activity of both latent forms of gelatinases in blood plasma of rats with cardiopathy. It is concluded that the stabilization of gelatinases activity is an indicator of myocardial metabolism and additional indicator of fibrosis development.
Keywords
Full Text:
PDF (Українська)References
1. Багрий А.Э., Чумаченко Н.В., Цыба Н.Ю. Оценка плазменных уровней ММП-2 и -9 в прогнозировании ремоделирования левого желудочка у больных с острым инфарктом миокарда с элевацией ST. Питання експериментальної та клінічної медицини, 2010; 14(1): 23-26. | |
| |
2. Ватутин Н.Т., Калинкина Н.В., Кетинг Е.В. Антрациклиновая кардиомиопатия. Донецк: ДонГИИИ, 2001. - 236 с. | |
| |
3. Калинкина Н.В. Патогенез антрациклиновых повреждений сердца. Журнал Академії медичних наук України, 2005; 11(2): 238-250. | |
| |
4. Куликов В.Ю. Роль окислительного стресса в регуляции метаболической активности внеклеточного матрикса соединительной ткани. Медицина и образование в Сибири, 2009; 4. | |
| |
5. Agewall S. Matrix metalloproteinases and cardiovascular disease. Eur. Heart J, 2006; 27: 121-122. | |
| |
6. Aupperle H., Garbade J., Schubert A. Effects of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinases and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model. Vet. Pathol, 2007; 44: 494-503. | |
| |
7. Belton O., Byrne D., Kearney D. et al. Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation, 2000; 102: 840-845. | |
| |
8. Bombardier C., Lane L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl. J. Med, 2000; 343: 1520-1528. | |
| |
9. Burleigh M.E., Babaev V.R., Oates J.A. et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice. Circulation, 2002; 105: 1816-1823. | |
| |
10. Chenevard R., Hurlimann D., Bechir M. et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation, 2003; 107: 405-409. | |
| |
11. Cipollone F. COX-2 and Atherosclerosis. J. of Cardiovascular Pharmacology, 2006; 47: 826-836. | |
| |
12. Dowd N.P., Scully V., Adderley Sh.R., Cunningham A.J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest, 2001; 108: 585-590. | |
| |
13. Lakhanpal P., Kumar Rai D. Role of quercetin in cardiovascular diseases. Internet Journal of Medical Update, 2008; 3(1): 31-49. | |
| |
14. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001; 286: 954-959. | |
| |
15. Murphy G., Nagase H. Progress in matrix metalloproteinase research. Mol. Aspects Med, 2010; 29(5): 1-33. | |
| |
16. Troeberg L., Nagase H. Current Protocols in Protein. Science, 2003; 21: 15. | |
Refbacks
- There are currently no refbacks.
Copyright (c) 2010 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.